Inclusion Criteria:

          -  1. Men and Women and members of all ethnic groups who are at least 18 years old at the
             time of enrollment are eligible for this trial;

          -  2. Informed consent obtained and signed;

          -  3. Willing and able to commit to study procedures including long-term follow-up
             visit(s);

          -  4. Histopathologically confirmed WHO grade IV recurrent glioblastoma (GBM).

          -  5. In all cases, the diagnosis must be confirmed by a pathologist.

          -  6. Recurrent surgically resectable tumor and/or biopsy;

          -  7. Participants who have undergone surgical resection should have received an MRI or a
             scan after surgery in order to visualize residual tumor. If not, the operative report
             must be available;

          -  8. Start of radiotherapy, if indicated, must occur at least 2 weeks after surgery
             and/or biopsy;

          -  9. Estimated survival of at least 3 months;

          -  10. Hgb > 9 gm; absolute neutrophil count (ANC) > 1500/μl; platelets > 100,000;
             Creatinine < 1.5 times the upper limit of laboratory normal value; Bilirubin < 2 times
             the upper limit of laboratory normal value; serum glutamate pyruvate transaminase
             (SGPT) or serum glutamate oxaloacetate transaminase (SGOT) < 3 times the upper limit
             of laboratory normal value;

          -  11. If indicated radiation therapy and chemotherapy must start within 8 weeks of tumor
             resection or biopsy.

        Exclusion Criteria:

          -  1. Subjects with newly diagnosed GBM

          -  2. Pregnant women or nursing mothers cannot participate in the study. Women of
             childbearing age must have a negative pregnancy test within 72 hours prior to study
             entry. Women of childbearing potential must practice medically approved contraceptive
             precautions;

          -  3. Abnormal hematological results at inclusion with: Neutrophils < 1,500/mm3;
             Blood-platelets < 100,000/mm3

          -  4. Severe or chronic renal insufficiency (creatinine clearance ≤ 30 ml/min);

          -  5. Patient unable to follow procedures, visits, examinations described in the study;

          -  6. Any usual formal indication against imaging examinations (important claustrophobia,
             pacemaker);